JAMA Network
About The Study: Extended low-intensity anticoagulation with apixaban was associated with a reduction in symptomatic superficial vein thrombosis (SuVT) in patients with provoked venous thromboembolism with enduring risk factors for recurrence. Further randomized clinical trials specifically focused on SuVT are needed to ascertain optimal antithrombotic strategies in broader populations at risk of SuVT.
/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.
